Dermata Therapeutics, Inc. (DRMA)
DRMA Stock Price Chart
Explore Dermata Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DRMA price movements and trends.
DRMA Company Profile
Discover essential business fundamentals and corporate details for Dermata Therapeutics, Inc. (DRMA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Aug 2021
Employees
8.00
Website
https://www.dermatarx.comCEO
Gerald T. Proehl
Description
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
DRMA Financial Timeline
Browse a chronological timeline of Dermata Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Aug 2026
EPS estimate is -$0.55.
Earnings released on 13 May 2026
EPS came in at -$0.48 surpassing the estimated -$0.53 by +9.43%.
Earnings released on 26 Mar 2026
EPS came in at -$1.52 surpassing the estimated -$1.54 by +1.30%.
Earnings released on 14 Nov 2025
EPS came in at -$1.65 falling short of the estimated -$1.59 by -3.77%.
Earnings released on 13 Aug 2025
EPS came in at -$1.66 surpassing the estimated -$2.90 by +42.76%.
Stock split effective on 1 Aug 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$4.50 falling short of the estimated -$0.45 by -900.00%.
Earnings released on 17 Mar 2025
EPS came in at -$3.15 falling short of the estimated -$1.50 by -110.00%.
Earnings released on 13 Nov 2024
EPS came in at -$2.04 surpassing the estimated -$2.64 by +22.73%.
Earnings released on 7 Aug 2024
EPS came in at -$4.18 falling short of the estimated -$3.79 by -10.29%.
Stock split effective on 16 May 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at -$7.05 falling short of the estimated -$5.40 by -30.56%.
Earnings released on 21 Mar 2024
EPS came in at -$3.15 falling short of the estimated -$0.78 by -303.85%.
Earnings released on 9 Nov 2023
EPS came in at -$8.10 falling short of the estimated -$0.63 by -1.19k%.
Earnings released on 10 Aug 2023
EPS came in at -$9.45 falling short of the estimated -$0.92 by -927.17%.
Earnings released on 11 May 2023
EPS came in at -$34.03 falling short of the estimated -$2.65 by -1.18k%.
Stock split effective on 14 Mar 2023
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 21 Feb 2023
EPS came in at -$28.79 falling short of the estimated $3.20 by -999.69%.
Earnings released on 10 Nov 2022
EPS came in at -$47.98 falling short of the estimated -$3.52 by -1.26k%.
Earnings released on 15 Aug 2022
EPS came in at -$57.57 falling short of the estimated -$5.12 by -1.02k%.
Earnings released on 16 May 2022
EPS came in at -$79.16 falling short of the estimated -$6.40 by -1.14k%.
Earnings released on 28 Mar 2022
EPS came in at -$4.16 surpassing the estimated -$5.68 by +26.76%.
Earnings released on 15 Nov 2021
EPS came in at -$13.76 falling short of the estimated -$7.36 by -86.96%.
Earnings released on 27 Sept 2021
EPS came in at -$11.20 surpassing the estimated -$22.56 by +50.35%.
Earnings released on 16 Aug 2021
EPS came in at -$4.43 .
DRMA Stock Performance
Access detailed DRMA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
